

Karel Pavelka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6856925/publications.pdf>

Version: 2024-02-01

222
papers

28,952
citations

34016

52
h-index

5663

162
g-index

236
all docs

236
docs citations

236
times ranked

28707
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. <i>Scientific Reports</i> , 2021, 11, 1.	1.6	9,439
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
4	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. <i>Lancet</i> , The, 2004, 363, 675-681.	6.3	1,662
5	The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. <i>Arthritis and Rheumatism</i> , 2006, 54, 26-37.	6.7	1,634
6	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
7	EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1125-1135.	0.5	1,033
8	Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis. <i>Archives of Internal Medicine</i> , 2002, 162, 2113.	4.3	584
9	Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. <i>Lancet</i> , The, 2013, 381, 1541-1550.	6.3	568
10	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008, 58, 3319-3329.	6.7	539
11	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.5	394
12	Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1895-1904.	0.5	345
13	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. <i>Lancet</i> , The, 2013, 381, 918-929.	6.3	311
14	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet</i> , The, 2014, 383, 321-332.	6.3	232
15	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1575-1580.	0.5	188
16	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1898-1904.	0.5	165
17	Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. <i>Arthritis Research and Therapy</i> , 2017, 19, 285.	1.6	161
18	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1679-1687.	0.5	138

#	ARTICLE	IF	CITATIONS
19	Natural Selection and Population History in the Human Angiotensinogen Gene (AGT): 736 Complete AGT Sequences in Chromosomes from Around the World. <i>American Journal of Human Genetics</i> , 2004, 74, 898-916.	2.6	122
20	Prospective new biological therapies for rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009, 9, 102-107.	2.5	119
21	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. <i>Drugs and Aging</i> , 2016, 33, 75-85.	1.3	116
22	GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 869-877.	0.5	114
23	Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012, 94, 2113-2119.	1.4	107
24	Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. <i>Menopause</i> , 2004, 11, 138-143.	0.8	104
25	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
26	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. <i>Arthritis Care and Research</i> , 2017, 69, 1287-1296.	1.5	95
27	Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1410-1411.	0.5	94
28	Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1621-1627.	0.5	93
29	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. <i>PLoS ONE</i> , 2017, 12, e0175207.	1.1	92
30	COL6A1, the Candidate Gene for Ossification of the Posterior Longitudinal Ligament, Is Associated With Diffuse Idiopathic Skeletal Hyperostosis in Japanese. <i>Spine</i> , 2005, 30, 2321-2324.	1.0	91
31	Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: Putative involvement in the pathogenesis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 779-789.	6.7	91
32	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1950-1954.	0.5	91
33	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018, 32, 397-404.	2.2	82
34	Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONDroitin versus CElecoxib versus Placebo Trial (CONCEPT). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1537-1543.	0.5	75
35	The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. <i>Rheumatology</i> , 2014, 53, 1520-1526.	0.9	72
36	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.5	71

#	ARTICLE	IF	CITATIONS
37	Predictive map of Ixodes ricinus high-incidence habitats and a tick-borne encephalitis risk assessment using satellite data. <i>Experimental and Applied Acarology</i> , 1998, 22, 417-433.	0.7	70
38	Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R122.	1.6	69
39	Acute Effects of Glucocorticoids on Serum Markers of Osteoclasts, Osteoblasts, and Osteocytes. <i>Calcified Tissue International</i> , 2013, 92, 354-361.	1.5	68
40	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 374-377.	0.5	64
41	Leflunomide in psoriatic arthritis: Results from a large European prospective observational study. <i>Arthritis Care and Research</i> , 2013, 65, 464-470.	1.5	64
42	A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Journal of Rheumatology</i> , 2015, 42, 912-919.	1.0	64
43	Functional non-synonymous variants of ABCG2 and gout risk. <i>Rheumatology</i> , 2017, 56, 1982-1992.	0.9	62
44	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 96-102.	0.5	61
45	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 252.	1.6	60
46	Efficacy and safety of piacledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. <i>Clinical Rheumatology</i> , 2010, 29, 659-670.	1.0	59
47	An update on biomarkers in axial spondyloarthritis. <i>Autoimmunity Reviews</i> , 2016, 15, 501-509.	2.5	58
48	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1536-1544.	0.5	58
49	Oral therapy with proteolytic enzymes decreases excessive TGF- β^2 levels in human blood. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, S10-S15.	1.1	55
50	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1336-1342.	0.5	55
51	The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. <i>Arthritis Research and Therapy</i> , 2019, 21, 77.	1.6	55
52	Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1276-1282.	0.5	51
53	MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 170-177.	0.5	48
54	MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 124.	1.6	48

#	ARTICLE	IF	CITATIONS
55	Characterization of Monoclonal Antibodies Recognizing Different Fragments of Cartilage Oligomeric Matrix Protein in Human Body Fluids. <i>Archives of Biochemistry and Biophysics</i> , 1997, 341, 8-16.	1.4	46
56	Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 14.	0.8	44
57	Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. <i>Cytokine</i> , 2015, 73, 36-43.	1.4	44
58	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. <i>Rheumatology</i> , 2021, 60, 820-828.	0.9	41
59	Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1590-1594.	0.9	40
60	Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 275.	1.6	40
61	Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA. <i>Clinica Chimica Acta</i> , 2003, 328, 59-69.	0.5	39
62	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	1.6	37
63	Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2015, 34, 563-571.	1.0	36
64	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36
65	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 176.	0.8	36
66	Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 79.	1.6	35
67	Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-6.	1.4	34
68	Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1989380.	1.2	34
69	Complex Analysis of Urate Transporters SLC2A9, SLC22A12 and Functional Characterization of Non-Synonymous Allelic Variants of GLUT9 in the Czech Population: No Evidence of Effect on Hyperuricemia and Gout. <i>PLoS ONE</i> , 2014, 9, e107902.	1.1	33
70	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the European-European registry collaboration for abatacept (PANABA). <i>Clinical Rheumatology</i> , 2017, 36, 773-779.	1.0	33
71	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280.	1.8	33
72	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. <i>PLoS ONE</i> , 2017, 12, e0183420.	1.1	32

#	ARTICLE	IF	CITATIONS
73	Intraindividual Differences in Pain Relief and Functional Improvement in Osteoarthritis with Diclofenac or Tramadol. <i>Clinical Drug Investigation</i> , 1998, 16, 421-429.	1.1	31
74	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. <i>Cytokine</i> , 2011, 55, 116-121.	1.4	31
75	S100A4 (Mts1): Is there any relation to the pathogenesis of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2006, 5, 129-131.	2.5	30
76	Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. <i>PLoS ONE</i> , 2017, 12, e0185323.	1.1	30
77	An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 84.	1.6	30
78	Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. <i>ACR Open Rheumatology</i> , 2020, 2, 119-127.	0.9	30
79	Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0132674.	1.1	28
80	Osteonecrosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2000, 14, 399-414.	1.4	26
81	Enthesal involvement in patients with systemic lupus erythematosus: an ultrasound study. <i>Rheumatology</i> , 2018, 57, 1822-1829.	0.9	26
82	An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. <i>Rheumatology</i> , 2020, 59, 3858-3868.	0.9	26
83	Clinical Efficacy of Etanercept Versus Sulfasalazine in Ankylosing Spondylitis Subjects with Peripheral Joint Involvement. <i>Journal of Rheumatology</i> , 2012, 39, 836-840.	1.0	25
84	Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. <i>BMC Research Notes</i> , 2013, 6, 115.	0.6	25
85	Decreased Circulating Visfatin Is Associated with Improved Disease Activity in Early Rheumatoid Arthritis: Data from the PERAC Cohort. <i>PLoS ONE</i> , 2014, 9, e103495.	1.1	25
86	Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. <i>Rheumatology</i> , 2016, 55, 191-194.	0.9	24
87	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. <i>Clinical Rheumatology</i> , 2018, 37, 2055-2062.	1.0	23
88	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. <i>Rheumatology International</i> , 2019, 39, 469-478.	1.5	23
89	Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee. <i>Osteoarthritis and Cartilage</i> , 1995, 3, 15-23.	0.6	22
90	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. <i>RMD Open</i> , 2019, 5, e000994.	1.8	22

#	ARTICLE	IF	CITATIONS
91	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	0.9	20
92	Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 230-236.	0.9	20
93	Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 264.	0.8	20
94	Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. <i>Current Medical Research and Opinion</i> , 2004, 20, 1967-1977.	0.9	19
95	Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study. <i>BMC Musculoskeletal Disorders</i> , 2005, 6, 31.	0.8	19
96	Hip Fracture Incidence from 1981 to 2009 in the Czech Republic as a Basis of the Country-Specific FRAX Model. <i>Calcified Tissue International</i> , 2012, 90, 365-372.	1.5	19
97	The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. <i>Cytokine</i> , 2013, 64, 441-447.	1.4	19
98	Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 308.	0.8	19
99	Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 17-24.	1.6	19
100	Biologic registries in rheumatology: Lessons learned and expectations for the future. <i>Autoimmunity Reviews</i> , 2012, 12, 329-336.	2.5	18
101	No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2012, 31, 67-71.	1.0	18
102	Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic – data from the ATTRA registry. <i>Clinical Rheumatology</i> , 2013, 32, 1451-1458.	1.0	18
103	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment – results from 12 countries in EuroSpA. <i>Rheumatology</i> , 2020, 59, 1640-1650.	0.9	18
104	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. <i>Rheumatology</i> , 2015, 54, kev260.	0.9	17
105	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017, 44, 162-169.	1.0	17
106	Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. <i>RMD Open</i> , 2018, 4, e000809.	1.8	17
107	Prevalence and distribution of cartilage damage at the metacarpal head level in rheumatoid arthritis and osteoarthritis: an ultrasound study. <i>Rheumatology</i> , 2019, 58, 1206-1213.	0.9	17
108	Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. <i>Cytokine</i> , 2019, 116, 13-20.	1.4	17

#	ARTICLE	IF	CITATIONS
109	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020, 6, e001211.	1.8	17
110	S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. <i>Scientific Reports</i> , 2021, 11, 6063.	1.6	17
111	Knowledge of osteoporosis correlated with hormone therapy use and health status. <i>Maturitas</i> , 2007, 56, 21-29.	1.0	16
112	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2012, 51, v12-v21.	0.9	16
113	The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 51.	0.8	16
114	Maintenance of remission with combination etanercept+DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. <i>Rheumatology International</i> , 2017, 37, 1469-1479.	1.5	16
115	Changes in Structure and Symptoms in Knee Osteoarthritis and Prediction of Future Knee Replacement Over 8 Years. <i>Calcified Tissue International</i> , 2013, 93, 502-507.	1.5	15
116	Induction of response with etanercept+methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. <i>Clinical Rheumatology</i> , 2013, 32, 1275-1281.	1.0	15
117	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. <i>RMD Open</i> , 2016, 2, e000228.	1.8	15
118	The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis – a cohort study. <i>Arthritis Research and Therapy</i> , 2017, 19, 5.	1.6	15
119	Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. <i>Scientific Reports</i> , 2019, 9, 11218.	1.6	15
120	Symptomatic treatment of osteoarthritis: paracetamol or NSAIDs?. <i>International Journal of Clinical Practice</i> , 2005, 58, 5-12.	0.8	14
121	Self-reported compliance with osteoporosis medication – Qualitative aspects and correlates. <i>Maturitas</i> , 2008, 60, 223-229.	1.0	14
122	Hyperuricemia and gout due to deficiency of hypoxanthine+guanine phosphoribosyltransferase in female carriers: New insight to differential diagnosis. <i>Clinica Chimica Acta</i> , 2015, 440, 214-217.	0.5	14
123	Biomarkers of hand osteoarthritis. <i>Rheumatology International</i> , 2018, 38, 725-735.	1.5	14
124	Earthen Jewish Architecture of Southern Morocco: Documentation of Unfired Brick Synagogues and Mellahs in the Drâa-Tafilalet Region. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1712.	1.3	14
125	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. <i>PLoS ONE</i> , 2016, 11, e0165498.	1.1	14
126	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. <i>Biomarkers</i> , 2015, 20, 47-51.	0.9	12

#	ARTICLE	IF	CITATIONS
127	AUTOMATIC CLASSIFICATION OF POINT CLOUDS FOR HIGHWAY DOCUMENTATION. Acta Polytechnica, 2018, 58, 165.	0.3	12
128	Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. Arthritis Research and Therapy, 2014, 16, 460.	1.6	11
129	Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 203-211.	0.7	11
130	A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis. BMC Musculoskeletal Disorders, 2017, 18, 2.	0.8	11
131	High Resolution Drone Surveying of the Pista Geoglyph in Palpa, Peru. Geosciences (Switzerland), 2018, 8, 479.	1.0	11
132	Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology, 2019, 58, 2221-2229.	0.9	11
133	Some principles of the development of a clinical database/national register of selected inflammatory rheumatic diseases in the Czech Republic. International Journal of Medical Informatics, 2006, 75, 216-223.	1.6	10
134	Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF α therapy and discontinuation of glucocorticoids. Rheumatology International, 2013, 33, 2001-2007.	1.5	10
135	Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis. Cytokine, 2017, 97, 187-192.	1.4	10
136	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. Scientific Reports, 2021, 11, 11525.	1.6	10
137	A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. Rheumatology and Therapy, 2021, 8, 1775-1787.	1.1	10
138	Adipokine profile is modulated in subcutaneous adipose tissue by TNF α inhibitors in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 2054-2056.	0.5	9
139	Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open, 2019, 9, e024713.	0.8	9
140	Examples of different techniques for glaciers motion monitoring using InSAR and RPAS. European Journal of Remote Sensing, 2019, 52, 219-232.	1.7	8
141	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Research and Therapy, 2021, 23, 173.	1.6	8
142	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. Clinical and Experimental Rheumatology, 2019, 37, 342-343.	0.4	8
143	Photogrammetric Co-Processing of Thermal Infrared Images and RGB Images. Sensors, 2022, 22, 1655.	2.1	8
144	Adalimumab in the treatment of rheumatoid arthritis. Aging Health, 2006, 2, 533-545.	0.3	7

#	ARTICLE	IF	CITATIONS
145	Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis. <i>Patient</i> , 2018, 11, 329-340.	1.1	7
146	RPAS for documentation of Nazca aqueducts. <i>European Journal of Remote Sensing</i> , 2019, 52, 174-181.	1.7	7
147	Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis. <i>Clinical Rheumatology</i> , 2019, 38, 173-179.	1.0	7
148	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 2455-2461.	0.9	7
149	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021, 48, 48-57.	1.0	7
150	High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. <i>Scientific Reports</i> , 2021, 11, 4719.	1.6	7
151	Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 358-366.	0.4	7
152	European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. <i>Rheumatology</i> , 2022, 61, 3799-3807.	0.9	7
153	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. <i>Rheumatology International</i> , 2019, 39, 1037-1043.	1.5	6
154	Study of Erbil Al-Qala citadel time changes by comparison of historical and contemporary image data. <i>European Journal of Remote Sensing</i> , 2019, 52, 202-208.	1.7	6
155	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. <i>Rheumatology</i> , 2021, 60, 5060-5072.	0.9	6
156	Pentosidine, an Advanced Glycation End-Product, May Reflect Clinical and Morphological Features of Hand Osteoarthritis. <i>Open Rheumatology Journal</i> , 2012, 6, 64-69.	0.1	6
157	Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2015, 159, 562-568.	0.2	6
158	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. <i>Drugs in Context</i> , 2020, 9, 1-15.	1.0	6
159	Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: Comment on the article by Brandt and Mazzuca. <i>Arthritis and Rheumatism</i> , 2006, 54, 2339-2341.	6.7	5
160	Treatment of atlanto-axial subluxation secondary to rheumatoid arthritis by short segment stabilization with polyaxial screws. <i>Acta Neurochirurgica</i> , 2017, 159, 1791-1801.	0.9	5
161	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 183-192.	1.4	5
162	Knud Rasmussen Glacier Status Analysis Based on Historical Data and Moving Detection Using RPAS. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 754.	1.3	5

#	ARTICLE	IF	CITATIONS
163	Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , 2021, 23, 11.	1.6	5
164	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. <i>Biomedicines</i> , 2021, 9, 650.	1.4	5
165	Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. <i>Biomolecules</i> , 2021, 11, 4.	1.8	5
166	UAV remote sensing capability for precision agriculture, forestry and small natural reservation monitoring. <i>Proceedings of SPIE</i> , 2017, , .	0.8	4
167	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2019, 38, 2411-2421.	1.0	4
168	STRUCTURE FROM MOTION PROCESSING OF ANALOGUE IMAGES CAPTURED BY ROLLEI METRIC CAMERA, DIGITIZED WITH VARIOUS SCANNING RESOLUTION. <i>Acta Polytechnica</i> , 2020, 60, 288-302.	0.3	4
169	The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 1823-1831.	0.9	4
170	FRI0378â€¦DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? â€œ RESULTS FROM THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		3
171	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. <i>Biomarkers in Medicine</i> , 2021, 15, 5-13.	0.6	3
172	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. <i>Rheumatology International</i> , 2022, 42, 803-814.	1.5	3
173	Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 415-430.	0.3	2
174	Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A13.2-A14.	0.5	2
175	USE OF HISTORICAL IMAGES FOR OBJECT RECONSTRUCTION. , 2013, , .		2
176	Creating a Material Spectral Library for Plaster and Mortar Material Determination. <i>Materials</i> , 2021, 14, 7030.	1.3	2
177	Prevalence and distribution of cartilage and bone damage at metacarpal head in healthy subjects. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1394-1401.	0.4	2
178	Hypotheses about geoglyphs at Nasca, Peru: new discoveries. <i>Geoinformatics FCE CTU</i> , 2016, 15, 85-97.	0.4	1
179	Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. <i>Clinical Rheumatology</i> , 2018, 37, 1417-1420.	1.0	1
180	FRI0404â€¦POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
181	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. BMC Rheumatology, 2020, 4, 13.	0.6	1
182	Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. Vnitřni Lekarství, 2021, 67, 195-200.	0.1	1
183	Transformations in the Photogrammetric Co-Processing of Thermal Infrared Images and RGB Images. Sensors, 2021, 21, 5061.	2.1	1
184	Clinical effectiveness and safety of intra-articular injection of HYALGO in the management of knee osteoarthritis symptoms: A multicenter prospective study. Journal of Clinical Orthopaedics and Trauma, 2021, 19, 75-80.	0.6	1
185	Using of both hyperspectral aerial sensing and RPAS multispectral sensing for potential archaeological sites detection. , 2018, , .		1
186	USING TERRESTRIAL AND AERIAL PHOTOGRAMMETRY IN ARCHAEOLOGY. , 2019, , .		1
187	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology, 2019, 37, 338-339.	0.4	1
188	Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210816.	1.2	1
189	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. Clinical and Experimental Rheumatology, 0, , .	0.4	1
190	Comparaison des signes cliniques, radiographiques, biologiques et scintigraphiques dans l'arthrose érosive et non érosive de la main. Résultats après deux ans de suivi. Revue Du Rhumatisme (Edition) Tj ETQ000 0 rgBT /Overlock		
191	World Congress on Osteoarthritis (Osteoarthritis Research Society International). Future Rheumatology, 2007, 2, 129-132.	0.2	0
192	Modulation of subcutaneous adipose tissue adipokines by TNF- α blockade therapy in patients with inflammatory arthritides. Annals of the Rheumatic Diseases, 2011, 70, A85-A85.	0.5	0
193	A7.3 Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A48.3-A49.	0.5	0
194	Hyperspectral approach to a non-invasive survey of cultural heritage objects. , 2013, , .		0
195	08.48 Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
196	08.49 Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients " preliminary data from a single-centre controlled study. , 2017, , .		0
197	02.37 IL-37 is associated with increased atherogenesis rather than disease activity in patients with rheumatoid arthritis. , 2017, , .		0
198	08.47 Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
199	O2.39â€¦Clusterin is increased in idiopathic inflammatory myopathies and is associated with disease activity. , 2017, , .		0
200	O2.30â€¦High levels of mir-451a differentiate patients with clinically suspect arthralgia from healthy controls. , 2017, , .		0
201	FRI0403â€¦HIGH BASELINE PATIENTâ€™S COMPARED WITH EVALUATORâ€™S GLOBAL ASSESSMENT IS ASSOCIATED WITH LOWER RETENTION AND REMISSION RATES OF FIRST TNF INHIBITOR IN AXSPA PATIENTS â€œ DATA FROM THE EUROSPA COLLABORATION. , 2019, , .		0
202	THU0373â€¦ACTIVE SACROILIITIS ON MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANTERIOR UVEITIS. , 2019, , .		0
203	AB0687â€¦EFFECTIVENESS OF SPECIALIZED AND INTENSIVE ADL TRAINING IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES â€œ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
204	THU0453â€¦PROGRESSION OF PAIN, NUMBER OF PAINFUL AND SWOLLEN JOINTS AND ULTRASOUND DETECTED CHANGES IN THE GROUP OF 133 PATIENTS WITH HAND OSTEOARTHRITIS OVER THREE YEARS. , 2019, , .		0
205	FRI0107â€¦THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRY. , 2019, , .		0
206	THU0638â€¦CONSIDERATIONS FOR IMPROVING QUALITY OF CARE IN RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES. , 2019, , .		0
207	OP0066â€¦EFFECTIVENESS OF SPECIALIZED HAND/FACE PHYSICAL-OCCUPATIONAL THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS â€œ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
208	THU0101â€¦TORQUE TENO VIRAL LOAD FOR MONITORING OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS. , 2019, , .		0
209	FRI0379â€¦LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL. , 2019, , .		0
210	FRI0634â€¦STANDARD REFERENCE VALUES OF METACARPAL HEAD CARTILAGE THICKNESSMEASUREMENT BY ULTRASOUND IN HEALTHY SUBJECTS. , 2019, , .		0
211	THU0062â€¦THE DYSREGULATION OF NK CELLS AND NON-CLASSICAL AND CLASSICAL MONOCYTE SUBPOPULATIONS IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS. , 2019, , .		0
212	THU0383â€¦PREVALENCE OF SPONDYLOARTHRITIS IN FIRST DEGREE RELATIVES OF PATIENTS WITH ANKYLOSING SPONDYLITIS. , 2019, , .		0
213	P200â€¦fCharacterisation of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators. Rheumatology, 2020, 59, .	0.9	0
214	OUP accepted manuscript. Rheumatology, 2021, , .	0.9	0
215	Astronomical Investigation to Verify the Calendar Theory of the Nasca Lines. Applied Sciences (Switzerland), 2021, 11, 1637.	1.3	0
216	P127â€¦fTreating rheumatoid arthritis patients with moderate disease activity: an analysis of the upadacitinib SELECT Phase III randomised studies. Rheumatology, 2021, 60, .	0.9	0

#	ARTICLE	IF	CITATIONS
217	USING SATELLITE IMAGES FOR DOCUMENTATION OF DAMAGES IN ALEPPO HISTORICAL CENTRE DURING CIVIL WAR. , 2018, , .		0
218	FROM DIGITAL PHOTOGRAPHY TO A VIRTUAL 3D. , 2018, , .		0
219	DOCUMENTATION OF VANISHING CULTURAL AND TECHNICAL HERITAGE. , 2019, , .		0
220	FROM PHOTOGRAMMETRICAL DOCUMENTATION TO VIRTUAL RECONSTRUCTION AND OBJECT REPLICATION. , 2019, , .		0
221	Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials. Rheumatology International, 2022, 42, 205-213.	1.5	0
222	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0